Sedana Medical AB (OSTO:SEDANA)

Q2 2026 Sedana Medical AB (publ) Earnings Call Transcript

Jul 17, 2026 / 11:30 AM GMT

Release Date Price: kr8.64 (-3.79%)

Transcript

Key Points

Positve

Sedana Medical AB (OSTO:SEDANA) achieved a significant milestone by submitting their New Drug Application (NDA) to the FDA in June, moving closer to entering the US market.
The company improved its profitability despite flat sales, with ex-US EBITDA reaching 2% in the quarter, up from zero a year ago.
Gross margins improved to 73% in the quarter, up from 70% last year, aided by lower costs of goods following the acquisition of their main supplier in Malaysia.
Sedana Medical AB (OSTO:SEDANA) secured a new loan facility with a local bank, providing access to 50 million SEC in additional funds, enhancing financial flexibility.
The company's other direct markets, including Spain, France, and the UK, showed strong growth, with a 41% increase at constant exchange rates, indicating successful market penetration and execution.

Negative

Sales in Germany, one of Sedana Medical AB (OSTO:SEDANA)'s key markets, declined by 22% at constant exchange rates due to lower ICU occupancy rates.
The company's overall net sales were flat compared to last year, with a slight decline of 1% year-over-year when excluding currency effects.
Cash and cash equivalents decreased significantly, from 81 million SEC at the beginning of the quarter to 52 million SEC, primarily due to investments related to the US program.
The company faces challenges in the German market, with a need to deepen penetration within existing accounts rather than opening new ones.
There is uncertainty regarding the FDA review process, which could lead to unforeseen costs and impact cash flow, despite preparations and mock audits conducted by the company.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SEDANA.ST - Sedana Medical AB (publ)
Q2 2026 Sedana Medical AB (publ) Earnings Call
Jul 17, 2026 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to today's FinWire presentation with Sedana Medical. After the presentation, there will be a question-and-answer session. So if you have any questions, you can submit them in English using the form on the right. With that said, I'll hand the floor to you. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you for the introduction. Warm welcome to our Q2 reports 2026. I'm here with our new CFO, Mikael Haag, who will introduce himself and speak about our financials in just a few minutes.

Peter Saki, our Chief Medical Officer

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.